Flamma Italy Expands With The Acquisition Of The Isso Plant

Gian Paolo Negrisoli, President and CEO, announced the acquisition in May 2012 and noted that “the future at Flamma is very bright and we are delighted to provide our customers with the knowledge that Flamma will grow to support their growth”.

In order to meet increasing worldwide customer demand, Flamma began to look at the possibility of expanding its capacity in Europe earlier this year. Initially considering expanding the existing facility in Chignolo d’Isola, Bergamo, the opportunity to acquire the nearby Isso facility presented itself.

The Isso facility is located east of Milano, 32 km (20 miles) or about 40 minutes from the Bergamo site. Based in an industrial area, the site has 5 buildings that include production, a drying department, R&D & analytical labs plus offices, utilities, and warehouses. The site was last inspected by the FDA in 2007. The acquisition of the Isso plant will double Flamma’s production capacity in Italy from 130 m3 to 270 m3 thus giving Flamma more flexibility for their current and future customers. Additionally, at Flamma Isso will be able to handle industrial quantities of triphosgene as well as ammonia gas.

The facility was previously owned by Erredue who had purchased the plant from Archimica (now part of the Euticals) in 2009.

Customers can expect the same Flamma cGMP quality standards from the Isso facility as soon as it is integrated into the Flamma Group. More importantly, Flamma will immediately increase the number of employees in R&D as well as the analytical department to support the high demand of resources brought on by new API projects.

Flamma Isso has been renovated over the past several months and will begin production October 1, 2012. Kenneth Drew, Ph.D., Director of US Sales and Business Development stated “The timing of Flamma Isso coming online is ideal for our current customer base. Flamma will have greater flexibility in order to move projects to completion as well as accommodate our customer’s ever changing project needs and demands. Meanwhile, new customers are excited about the possibilities to work with Flamma.”

About Flamma
The Flamma Group has grown in recent years to a total reactor capacity of 200 m3 over its two sites in Chignolo, Italy, and Dalian, China. The addition of the Isso (Italy) plant will increase their capacity to over 340 m3.

With 60+ years of experience, Flamma provides cGMP manufacturing services to the pharmaceutical industry from our FDA inspected site in Italy. Flamma’s self-managed non-cGMP facilities in China, Dalian Flamma Bioscience, offers cost-effective services to customers looking for a trusted partner in China. 

Flamma has expertise in the manufacture of small molecules and, more specifically, high value chiral materials as starting materials and/or key intermediates from early to late stage projects. Examples include sophisticated amino acids and compounds derived from amino acid chemistry including peptide fragments produced on large scale.

Flamma develops and produces APIs, either as NCEs or generics, for customers worldwide. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries.

As a fully integrated company Flamma is well positioned to help move compounds quickly along their path. Flamma attends a variety of industry events such as Informex, DCAT, BIO, ChemOutsourcing, and CPhI. For more information, visit http://www.flammagroup.com.